WSJ
06 Oct 2026, 08:35 UTC · 1h ago
Genmab Shares Climb After Positive Study Results for Blood-Cancer Drug
Impact · against what's priced in
Genmab's positive survival data for Epkinly in lymphoma patients provides a catalyst for potential label expansion and revenue growth. The efficacy results are expected to drive top-line growth in the coming fiscal year.
- NOVO+0.60
No priced-in read yet
- In context
The reported extension of survival time for patients with a common type of lymphoma suggests higher efficacy for Epkinly, likely accelerating regulatory approvals and expanding the drug's addressable market.
Read from the article alone
Search tags
